Artwork

Konten disediakan oleh Clinical Care Options, LLC and Clinical Care Options. Semua konten podcast termasuk episode, grafik, dan deskripsi podcast diunggah dan disediakan langsung oleh Clinical Care Options, LLC and Clinical Care Options atau mitra platform podcast mereka. Jika Anda yakin seseorang menggunakan karya berhak cipta Anda tanpa izin, Anda dapat mengikuti proses yang diuraikan di sini https://id.player.fm/legal.
Player FM - Aplikasi Podcast
Offline dengan aplikasi Player FM !

Current Clinical Practice and NCCN Guidelines for CLL/SLL

31:33
 
Bagikan
 

Manage episode 429566073 series 3256997
Konten disediakan oleh Clinical Care Options, LLC and Clinical Care Options. Semua konten podcast termasuk episode, grafik, dan deskripsi podcast diunggah dan disediakan langsung oleh Clinical Care Options, LLC and Clinical Care Options atau mitra platform podcast mereka. Jika Anda yakin seseorang menggunakan karya berhak cipta Anda tanpa izin, Anda dapat mengikuti proses yang diuraikan di sini https://id.player.fm/legal.

In this podcast episode, Farrukh Awan, MD, Jeremy S. Abramson, MD, MMSc, and Shuo Ma, MD, PhD, discuss real-world patient cases and how to align current clinical practice with the NCCN guidelines for CLL/SLL, including:

  • Prognostic variables when deciding between regimens
  • Role of MRD in CLL
  • Results from the phase II CAPTIVATE trial
  • Choosing among the available covalent BTK inhibitors
  • Preferred partner anti-CD20 antibody in CLL/SLL
  • Role of the noncovalent BTK inhibitor, pirtobrutinib, in CLL/SLL
  • Use of CAR T-cell therapy in CLL/SLL

Presenters:

Farrukh Awan, MD
Professor of Internal Medicine
Director of Lymphoid Malignancies Program
Harold C. Simmons Comprehensive Cancer Center
University of Texas Southwestern Medical Center
Dallas, Texas

Jeremy S. Abramson, MD, MMSc
Director, Center for Lymphoma
Massachusetts General Hospital
Associate Professor of Medicine
Harvard Medical School
Boston, Massachusetts

Shuo Ma, MD, PhD
Professor of Medicine
Division of Hematology-Oncology
Department of Medicine
Robert H. Lurie Comprehensive Cancer Center
Northwestern University
Feinberg School of Medicine
Chicago, Illinois

Content based on an online CME program supported by educational grants from BeiGene; Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC; and Lilly, and an independent medical education grant from AbbVie.

Link to full program:
https://bit.ly/3LzA2As

  continue reading

185 episode

Artwork
iconBagikan
 
Manage episode 429566073 series 3256997
Konten disediakan oleh Clinical Care Options, LLC and Clinical Care Options. Semua konten podcast termasuk episode, grafik, dan deskripsi podcast diunggah dan disediakan langsung oleh Clinical Care Options, LLC and Clinical Care Options atau mitra platform podcast mereka. Jika Anda yakin seseorang menggunakan karya berhak cipta Anda tanpa izin, Anda dapat mengikuti proses yang diuraikan di sini https://id.player.fm/legal.

In this podcast episode, Farrukh Awan, MD, Jeremy S. Abramson, MD, MMSc, and Shuo Ma, MD, PhD, discuss real-world patient cases and how to align current clinical practice with the NCCN guidelines for CLL/SLL, including:

  • Prognostic variables when deciding between regimens
  • Role of MRD in CLL
  • Results from the phase II CAPTIVATE trial
  • Choosing among the available covalent BTK inhibitors
  • Preferred partner anti-CD20 antibody in CLL/SLL
  • Role of the noncovalent BTK inhibitor, pirtobrutinib, in CLL/SLL
  • Use of CAR T-cell therapy in CLL/SLL

Presenters:

Farrukh Awan, MD
Professor of Internal Medicine
Director of Lymphoid Malignancies Program
Harold C. Simmons Comprehensive Cancer Center
University of Texas Southwestern Medical Center
Dallas, Texas

Jeremy S. Abramson, MD, MMSc
Director, Center for Lymphoma
Massachusetts General Hospital
Associate Professor of Medicine
Harvard Medical School
Boston, Massachusetts

Shuo Ma, MD, PhD
Professor of Medicine
Division of Hematology-Oncology
Department of Medicine
Robert H. Lurie Comprehensive Cancer Center
Northwestern University
Feinberg School of Medicine
Chicago, Illinois

Content based on an online CME program supported by educational grants from BeiGene; Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC; and Lilly, and an independent medical education grant from AbbVie.

Link to full program:
https://bit.ly/3LzA2As

  continue reading

185 episode

Semua episode

×
 
Loading …

Selamat datang di Player FM!

Player FM memindai web untuk mencari podcast berkualitas tinggi untuk Anda nikmati saat ini. Ini adalah aplikasi podcast terbaik dan bekerja untuk Android, iPhone, dan web. Daftar untuk menyinkronkan langganan di seluruh perangkat.

 

Panduan Referensi Cepat